(100 days)
The Arthrex SutureLoc™ Implant is intended to be used for suture (soft-tissue) fixation to bone in the knee for meniscal root repair.
The SutureLoc™ Implant is a suture construct comprised of a polyester sheath with multiple sutures assembled through the sheath.
This FDA 510(k) summary is for a medical device (SutureLoc™ Implant) and primarily focuses on demonstrating substantial equivalence to predicate devices based on technological characteristics and performance data. It does not describe a study involving an algorithm's performance, human readers, or expert adjudication as would be relevant for an AI/ML-based device.
Therefore, many of the requested fields regarding acceptance criteria, study design, sample sizes, ground truth, experts, and MRMC studies are not applicable or cannot be extracted from the provided text. The document describes performance testing for a physical implant, not a software algorithm.
Here's a breakdown of what can be extracted based on the provided text:
1. A table of acceptance criteria and the reported device performance
The document mentions performance data, but does not provide specific quantitative acceptance criteria or detailed reported performance values for each criterion in a table format. It generally states that testing was done to "demonstrate that the differences do not negatively impact mechanical strength" and that the device "meets pyrogen limit specifications."
| Acceptance Criteria (Inferred from testing mentioned) | Reported Device Performance (General Statement) |
|---|---|
| Mechanical Strength (Ultimate load and cyclic displacement) | Demonstrated that differences (from predicate) do not negatively impact mechanical strength. |
| Pyrogen Limit Specifications (Bacterial endotoxin per USP <85>) | Meets pyrogen limit specifications. |
| Packaging Integrity (Shelf-life, sterile barrier, protection during shipping/handling) | Confirmed the packaging design provides a protective sterile barrier and protects the integrity of the products post sterilization during shipping and handling. |
2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
The document does not provide details on the sample sizes used for the "ultimate load testing and cyclic displacement," "bacterial endotoxin," or "packaging testing." It does not mention data provenance (country of origin, retrospective/prospective).
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
Not applicable. This is a physical medical implant, not an AI/ML-based device requiring expert ground truth establishment for software performance.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
Not applicable.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
Not applicable. This is a physical medical implant.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
Not applicable. This is a physical medical implant.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
For mechanical testing, the "ground truth" would be the measured physical properties and performance characteristics against established engineering standards or against the predicate device's performance. For biocompatibility/safety, it's compliance with compendial standards like USP <85>. For packaging, it's meeting defined integrity and sterility standards.
8. The sample size for the training set
Not applicable. This is a physical medical implant, not an AI/ML-based device that requires a training set.
9. How the ground truth for the training set was established
Not applicable.
{0}------------------------------------------------
February 2, 2023
Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the FDA logo is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
Arthrex Inc. Erikka Edwardsen Regulatory Affairs Principal Specialist 1370 Creekside Boulevard Naples, Florida 34108-1945
Re: K223284
Trade/Device Name: SutureLocTM Implant Regulation Number: 21 CFR 888.3040 Regulation Name: Smooth or threaded metallic bone fixation fastener Regulatory Class: Class II Product Code: MBI Dated: December 23, 2022 Received: December 28, 2022
Dear Ms. Edwardsen:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for
{1}------------------------------------------------
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Sara S. Thompson -S
For
Laura C. Rose, Ph.D. Assistant Director DHT6C: Division of Restorative, Repair and Trauma Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K223284
Device Name SutureLoc™ Implant
Indications for Use (Describe)
The Arthrex SutureLoc™ Implant is intended to be used for suture (soft-tissue) fixation to bone in the knee for meniscal root repair.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ------------------------------------------------- | -- |
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
510(k) Summary
| Date Prepared | December 23, 2022 |
|---|---|
| 510(k) Number | K223284 |
| Submitter | Arthrex Inc.1370 Creekside BoulevardNaples, FL 34108-1945 |
| Contact Person | Erikka EdwardsenRegulatory Affairs Principal Specialist1-239-643-5553, ext. 70422rikka.edwardsen@arthrex.com |
| Name of Device | SutureLoc™ Implant |
| Common Name | Fastener, Fixation, Nondegradable, Soft Tissue |
| Product Code | MBI |
| Classification Name | 21 CFR 888.3040 Smooth or threaded metallic bone fixation fastener. |
| Regulatory Class | II |
| Predicate Device | K173845 Arthrex SwiveLock® Anchors |
| Reference Device | K203268 Arthrex Knotless FiberTak® |
| Purpose of Submission | This Traditional 510(k) premarket notification is submitted to obtain clearance forthe new Arthrex SutureLoc™ Implant. |
| Device Description | The SutureLoc™ Implant is a suture construct comprised of a polyester sheathwith multiple sutures assembled through the sheath. |
| Indications for Use | The Arthrex SutureLoc™ Implant is intended to be used for suture (soft-tissue)fixation to bone in the knee for meniscal root repair. |
| Summary of Technological Characteristics | The proposed device has the same intended use and fundamental technology asthe predicate and reference devices. The subject device is comprised of multiplesutures manufactured using the same materials as the Knotless FiberTak®(K203268) device. The primary differences include the stitching suture and use ofan accessory device to pull the anchor into the bone. |
| Performance Data | Ultimate load testing and cyclic displacement was performed on the subjectdevice to demonstrate that the differences do not negatively impact mechanicalstrength.Bacterial endotoxin per USP <85> was conducted to demonstrate that the devicemeets pyrogen limit specifications.Packaging testing was conducted to demonstrate shelf-life and confirm thepackaging design provides a protective sterile barrier and protects the integrity ofthe products post sterilization during shipping and handling. |
| Conclusion | The Arthrex SutureLoc™ Implant is substantially equivalent to the predicatedevices in which the basic design features, intended use and surgical techniqueare the same. Any differences between the subject device and the predicatedevices do not raised questions concerning safety and effectiveness.Based on the indications for use, technological characteristics, and the summaryof data submitted, Arthrex Inc. has determined that the proposed device issubstantially equivalent to the currently marketed predicate devices. |
§ 888.3040 Smooth or threaded metallic bone fixation fastener.
(a)
Identification. A smooth or threaded metallic bone fixation fastener is a device intended to be implanted that consists of a stiff wire segment or rod made of alloys, such as cobalt-chromium-molybdenum and stainless steel, and that may be smooth on the outside, fully or partially threaded, straight or U-shaped; and may be either blunt pointed, sharp pointed, or have a formed, slotted head on the end. It may be used for fixation of bone fractures, for bone reconstructions, as a guide pin for insertion of other implants, or it may be implanted through the skin so that a pulling force (traction) may be applied to the skeletal system.(b)
Classification. Class II.